Your browser doesn't support javascript.
loading
Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers.
Cortes, Jorge; Tamura, Kenji; DeAngelo, Daniel J; de Bono, Johann; Lorente, David; Minden, Mark; Uy, Geoffrey L; Kantarjian, Hagop; Chen, Lisa S; Gandhi, Varsha; Godin, Robert; Keating, Karen; McEachern, Kristen; Vishwanathan, Karthick; Pease, Janet Elizabeth; Dean, Emma.
Afiliação
  • Cortes J; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1901 East Road, Houston, TX, 77054, USA.
  • Tamura K; Department of Breast Oncology and Medical Oncology, National Cancer Center Hospital, 5-1-1 Tsukiji, Chuo, Tokyo, 104-0045, Japan.
  • DeAngelo DJ; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Room D-2050, Boston, MA, 02215, USA.
  • de Bono J; Prostate Cancer Targeted Therapy Group and Drug Development Unit, Royal Marsden, Downs Road, Sutton, Surrey, SM2 5PT, UK.
  • Lorente D; Prostate Cancer Targeted Therapy Group and Drug Development Unit, Royal Marsden, Downs Road, Sutton, Surrey, SM2 5PT, UK.
  • Minden M; Division of Stem Cell and Developmental Biology, Ontario Cancer Institute, Princess Margaret Hospital, 610 University Avenue, Toronto, ON, M5G 2M9, Canada.
  • Uy GL; Department of Medicine, Oncology Division, Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, MO, 63110, USA.
  • Kantarjian H; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1901 East Road, Houston, TX, 77054, USA.
  • Chen LS; Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1901 East Road, Houston, TX, 77054, USA.
  • Gandhi V; Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, 1901 East Road, Houston, TX, 77054, USA.
  • Godin R; AstraZeneca, 35 Gatehouse Dr, Waltham, MA, 02451, USA.
  • Keating K; AstraZeneca, 35 Gatehouse Dr, Waltham, MA, 02451, USA.
  • McEachern K; AstraZeneca, 35 Gatehouse Dr, Waltham, MA, 02451, USA.
  • Vishwanathan K; AstraZeneca, 35 Gatehouse Dr, Waltham, MA, 02451, USA.
  • Pease JE; AstraZeneca, 310 Cambridge Science Park, Milton Road, Cambridge, CB4 0FZ, UK.
  • Dean E; Clinical Trials Unit, The Christie NHS Foundation Trust, Manchester, M20 4BX, UK. emma.dean@astrazeneca.com.
Br J Cancer ; 118(11): 1425-1433, 2018 05.
Article em En | MEDLINE | ID: mdl-29765150
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Compostos de Bifenilo / Inibidores de Proteínas Quinases / Tiazolidinas / Neoplasias Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Compostos de Bifenilo / Inibidores de Proteínas Quinases / Tiazolidinas / Neoplasias Tipo de estudo: Clinical_trials / Guideline Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Br J Cancer Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Estados Unidos